A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

Eligibility Criteria

• 1. Has the ability to provide informed consent to participate in the study, in accordance with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 (R2) (2016) and applicable national and international regulations, before any protocol directed interventions are carried out.
• 2. Has an understanding, ability, and willingness to comply with Study procedures and restrictions.
• 3. Is 16 years or older at the time of screening.
• 4. First approximately 50 participants: congenital Type 1 VWD with a residual VWF antigen and/or activity less than 40 IU/dL (40%)
• 5. Has symptomatic disease as defined by a history of bruising or bleeding events, and typically experiencing bleeding symptoms every month.
• 1. Has a personal history of venous or arterial thrombosis or thromboembolic disease, except for catheter-associated, superficial vein thrombosis events.
• 2. Has a significant family history of unprovoked thromboembolic events in first degree relatives.
• 3. Has a congenital or acquired bleeding disorder other than VWD.
• 4. Has planned major surgery within the next 6 months.
• 5. Is pregnant or plans to become pregnant within the next 6 months.
• 6. Has any concurrent disease, treatment (including ongoing anticoagulation, antiplatelet, or non-steroidal anti-inflammatory drugs), condition, medication, or abnormality in clinical laboratory tests which may impact on the participant's bleeding symptoms or affect their ability to complete the study, in the Investigator's opinion.
• 7. Has received any investigational product within 30 days prior to screening.